Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $637.3K $554.2K $392.9K $806.2K $351.5K
SG&A Expense $815.9K $951.8K $1.1M $2.2M $319.9K
Operating Income $-2.3M $-724.4K $-3.0M $-4.1M $656.2K
Operating Margin
Interest Expense $175.0K $243.4K $32.6K $674 $681.8K
Pretax Income $-3.3M $-967.8K $-3.1M $-4.1M $-25.6K
Income Tax Expense $0 $0 $0 $0 $0
Net Income $-3.1M $-967.8K $-2.5M $-4.1M $-1.8M
Net Margin
EPS (Basic) $-0.12 $-0.04 $-0.10 $-0.18 $-0.14
EPS (Diluted) $-0.12 $-0.04 $-0.10 $-0.18 $-0.14
Shares Outstanding (Basic) 25.3M 24.7M 23.9M 23.6M 14.2M 5.5M
Shares Outstanding (Diluted) 25.3M 24.7M 23.9M 23.6M 14.2M 5.5M
Dividends Per Share
← Newer Page 2 of 2 Older →